Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
|
31562206 |
2020 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a blinded study, we detected ALK fusion from formalin-fixed paraffin-embedded lung cancer samples with a 100% 47) and genotyping /47) and genotyping (7/7).
|
31641223 |
2020 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The role of serum tumor markers (STMs) in the modern management of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in lung cancer remains poorly described.
|
31707279 |
2020 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to characterize the mechanisms of resistance to lorlatinib occurring in patients with <i>ALK</i>-rearranged lung cancer and design new therapeutic strategies in this setting.
|
31585938 |
2020 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This article reviewed the clinical significance and drug resistance mechanism of ALK rearrangement in lung cancer.
|
31559892 |
2020 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing.
|
31390053 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer.
|
31114237 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report a case of a patient with ALK-rearranged lung cancer progressing on three-lines of ALK-targeted therapies, with development of acquired resistance to lorlatinib, with both transformation to a neuroendocrine carcinoma, and acquisition of ALK 1196 M.
|
31319969 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in epidermal growth factor receptor (<i>EGFR</i>), and rearrangements of anaplastic lymphoma kinase (<i>ALK</i>) are targetable in lung cancer, while <i>BRAF</i> mutations have been successfully targeted in metastatic melanoma.
|
30886831 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The discovery of the EML4-ALK fusion kinase in 2007 was a breakthrough for this situation, and kinase fusion genes now form a group of relevant targetable oncogenes in lung cancer.
|
30941048 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
|
30902613 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
One strategy to overcome this drug resistance is to determine if novel cytotoxic agents retain the ability to kill lung cancer cells that have developed ALK inhibitor resistance.
|
31654622 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer.
|
30811109 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: These findings show that dual inhibition of HDAC and ALK receptor tyrosine kinase activities provides a means to circumvent crizotinib resistance in lung cancer.
|
30737231 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main aim of this review is to assemble on the efficacy of alectinib for the treatment of ALK+ NSCLC, to elaborate the activity of the drug in the central nervous system, and to debate on which is the position of this compound in the treatment course of ALK+ lung cancer patients.
|
31354290 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
|
30171175 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
BACKGROUND An extensive body of research reveals the clinical value of serum tumor markers in lung cancer patients, including carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCCA), cytokeratin-19 fragments (Cyfra21-1), and neuron-specific enolase (NSE), but little is known about the clinical properties of these serum tumor markers in anaplastic lymphoma kinase (ALK)-positive lung cancer patients.
|
30673691 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results show that the cytomorphological features of signet ring cells, nuclear grooves and nucleoli shape can help to triage a small amount of cytological and biopsy specimens for appropriate molecular testing of primary ALK (+) lung cancer.
|
30506595 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Crizotinib-Associated Renal Cysts in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients: A Single-Center Experience.
|
31480046 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We present the PET/CT findings of extensive disseminated genital herpes simplex virus infection in a 29-year-old woman known with disseminated anaplastic lymphoma kinase-mutated nonsmall lung cancer.
|
30829864 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
According to updated ALK testing guidelines from the College of American Pathologists, the International Association for the Study of Lung Cancer and the Association for Molecular Pathology published in 2018, ALK immunohistochemistry is formally an alternative to ALK FISH, and simultaneous detection of multiple hot spots, including, at least, <i>ALK</i>, <i>ROS1</i>, <i>RET</i>, <i>MET</i>, <i>ERBB2</i>, <i>BRAF</i> and <i>KRAS</i> genes is also recommended while performing next generation sequencing (NGS)-based testing.
|
31412611 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed 106 plasma specimens from 84 patients with advanced <i>ALK</i>-positive lung cancer treated with second- and third-generation ALK TKIs using a commercially available next-generation sequencing (NGS) platform (Guardant360).
|
31358542 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The second-generation ALK tyrosine kinase inhibitor brigatinib has recently been approved in the European Union for use after crizotinib treatment in patients with EML4-ALK-rearranged lung cancer.
|
31305295 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The natural histories of, and treatment options for, epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancers (NSCLCs) are distinctly different from those of lung cancer that lacks actionable mutations.
|
31346927 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The coexistence of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement in patients with multifocal lung adenocarcinomas (LUAC) constitutes a rare molecular subtype of lung cancer.
|
31138506 |
2019 |